These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 27788301)

  • 61. Average daily ischemic versus bleeding risk in patients with ACS undergoing PCI: Insights from the BleeMACS and RENAMI registries.
    D'Ascenzo F; Biolè C; Raposeiras-Roubin S; Gaido F; Abu-Assi E; Kinnaird T; Ariza-Solé A; Liebetrau C; Manzano-Fernández S; Boccuzzi G; Henriques JPS; Templin C; Wilton SB; Omedè P; Velicki L; Xanthopoulou I; Correia L; Cerrato E; Rognoni A; Fabrizio U; Nuñez-Gil I; Montabone A; Taha S; Fujii T; Durante A; Song X; Gili S; Magnani G; Autelli M; Bongiovanni F; Grosso A; Kawaji T; Blanco PF; Garay A; Quadri G; Alexopoulos D; Queija BC; Huczek Z; Paz RC; González-Juanatey JR; Fernández MC; Nie SP; Pousa IM; Kawashiri MA; Rettegno S; Gallo D; Morbiducci U; Conrotto F; Dominguez-Rodriguez A; Valdés M; Cequier A; Iñiguez-Romo A; Biondi-Zoccai G; Stone GW; De Ferrari GM
    Am Heart J; 2020 Feb; 220():108-115. PubMed ID: 31809991
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Thienopyridines in Acute Coronary Syndrome.
    Goodwin MM; Desilets AR; Willett KC
    Ann Pharmacother; 2011 Feb; 45(2):207-17. PubMed ID: 21304037
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
    Rafique AM; Nayyar P; Wang TY; Mehran R; Baber U; Berger PB; Tobis J; Currier J; Dave RH; Henry TD
    JACC Cardiovasc Interv; 2016 May; 9(10):1036-46. PubMed ID: 27198684
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Critical review of prasugrel for formulary decision makers.
    Schafer JA; Kjesbo NK; Gleason PP
    J Manag Care Pharm; 2009 May; 15(4):335-43. PubMed ID: 19422273
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
    Cavallari LH; Lee CR; Beitelshees AL; Cooper-DeHoff RM; Duarte JD; Voora D; Kimmel SE; McDonough CW; Gong Y; Dave CV; Pratt VM; Alestock TD; Anderson RD; Alsip J; Ardati AK; Brott BC; Brown L; Chumnumwat S; Clare-Salzler MJ; Coons JC; Denny JC; Dillon C; Elsey AR; Hamadeh IS; Harada S; Hillegass WB; Hines L; Horenstein RB; Howell LA; Jeng LJB; Kelemen MD; Lee YM; Magvanjav O; Montasser M; Nelson DR; Nutescu EA; Nwaba DC; Pakyz RE; Palmer K; Peterson JF; Pollin TI; Quinn AH; Robinson SW; Schub J; Skaar TC; Smith DM; Sriramoju VB; Starostik P; Stys TP; Stevenson JM; Varunok N; Vesely MR; Wake DT; Weck KE; Weitzel KW; Wilke RA; Willig J; Zhao RY; Kreutz RP; Stouffer GA; Empey PE; Limdi NA; Shuldiner AR; Winterstein AG; Johnson JA;
    JACC Cardiovasc Interv; 2018 Jan; 11(2):181-191. PubMed ID: 29102571
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Incidence and predictors of bleeding in ACS patients treated with PCI and prasugrel or ticagrelor: An analysis from the RENAMI registry.
    D'Ascenzo F; Grosso A; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Ali HH; Magnani G; Autelli M; Blanco PF; Garay A; Quadri G; Marra WG; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Raposeiras-Roubin S
    Int J Cardiol; 2018 Dec; 273():29-33. PubMed ID: 30228021
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Predictors of bleeding in patients with acute coronary syndromes treated with prasugrel.
    Widimsky P; Motovska Z; Bolognese L; Dudek D; Hamm C; Tanguay JF; Ten Berg J; Brown E; LeNarz L; Miller DL; Montalescot G;
    Heart; 2015 Aug; 101(15):1219-24. PubMed ID: 26060122
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.
    Abtan J; Steg PG; Stone GW; Mahaffey KW; Gibson CM; Hamm CW; Price MJ; Abnousi F; Prats J; Deliargyris EN; White HD; Harrington RA; Bhatt DL;
    JACC Cardiovasc Interv; 2016 Sep; 9(18):1905-13. PubMed ID: 27659566
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early thienopyridine treatment to improve primary PCI in patients with acute myocardial infarction).
    Zeymer U; Mochmann HC; Mark B; Arntz HR; Thiele H; Diller F; Montalescot G; Zahn R
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):147-154. PubMed ID: 25616919
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Clopidogrel versus prasugrel in acute coronary syndrome treated with coronary angioplasty].
    Lalor N; Rodríguez L; Elissamburu P; Filipini E; Conde D; Nau G; Cura F; Trivi M
    Medicina (B Aires); 2015; 75(4):207-12. PubMed ID: 26339874
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy).
    Stefanescu Schmidt AC; Kereiakes DJ; Cutlip DE; Yeh RW; D'Agostino RB; Massaro JM; Hsieh WH; Mauri L;
    Circulation; 2017 May; 135(18):1720-1732. PubMed ID: 28228427
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparison of prescription rates and clinical outcomes in acute coronary syndrome patients who underwent percutaneous coronary intervention using different P2Y
    Choe JC; Cha KS; Ahn J; Park JS; Lee HW; Oh JH; Choi JH; Lee HC; Hong TJ; Jeong MH;
    Int J Cardiol; 2019 Jan; 274():21-26. PubMed ID: 30224257
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
    Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
    Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Randomized, Double-Blind, Dose-Finding, Phase II Study of Prasugrel in Japanese Patients Undergoing Elective Percutaneous Coronary Intervention.
    Kimura T; Isshiki T; Ogawa H; Yokoi H; Yamaguchi T; Ikeda Y
    J Atheroscler Thromb; 2015; 22(6):557-69. PubMed ID: 25737192
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Safety and Efficacy in Prasugrel- Versus Ticagrelor-Treated Patients With ST-Elevation Myocardial Infarction.
    Dimitroulis D; Golabkesh M; Naguib D; Knoop B; Dannenberg L; Helten C; Pöhl M; Jung C; Kelm M; Zeus T; Polzin A
    J Cardiovasc Pharmacol; 2018 Oct; 72(4):186-190. PubMed ID: 29985284
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study.
    Secemsky EA; Yeh RW; Kereiakes DJ; Cutlip DE; Steg PG; Massaro JM; Apruzzese PK; Mauri L;
    JACC Cardiovasc Interv; 2017 May; 10(9):942-954. PubMed ID: 28473118
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland.
    Klingenberg R; Heg D; Räber L; Carballo D; Nanchen D; Gencer B; Auer R; Jaguszewski M; Stähli BE; Jakob P; Templin C; Stefanini GG; Meier B; Vogt P; Roffi M; Maier W; Landmesser U; Rodondi N; Mach F; Windecker S; Jüni P; Lüscher TF; Matter CM
    Heart; 2015 Jun; 101(11):854-63. PubMed ID: 25794517
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Study design and rationale for Optimal aNtiplatelet pharmacotherapy guided by bedSIDE genetic or functional TESTing in elective percutaneous coronary intervention patients (ONSIDE TEST): a prospective, open-label, randomised parallel-group multicentre trial (NCT01930773).
    Kołtowski Ł; Aradi D; Huczek Z; Tomaniak M; Sibbing D; Filipiak KJ; Kochman J; Balsam P; Opolski G
    Kardiol Pol; 2016; 74(4):372-9. PubMed ID: 26365936
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis.
    Lala A; Berger JS; Sharma G; Hochman JS; Scott Braithwaite R; Ladapo JA
    J Thromb Haemost; 2013 Jan; 11(1):81-91. PubMed ID: 23137413
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pericardial tamponade due to haemorrhagic pericardial effusion as a complication of prasugrel: a case report.
    Cader FA; Haq MM; Nasrin S; Karim MR
    BMC Cardiovasc Disord; 2016 Aug; 16(1):162. PubMed ID: 27577194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.